Business context and reporting period
This is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2023, filed August 8, 2023. The request metadata names Cervomed Inc., but the filing is for Diffusion Pharmaceuticals; the filing says the company would be renamed CervoMed if its proposed merger with EIP Pharma closes.
Diffusion historically developed TSC, a candidate intended to improve oxygen delivery to hypoxic tissues. It paused significant TSC development in Q1 2023, including a planned Phase 2 GBM study, while pursuing its merger with EIP.
Financial performance and position
| Metric | Q2 2023 / June 30, 2023 | Comparable period / prior year-end |
|---|---|---|
| Product revenue | None | None reported |
| Research and development expense | $72,185 for Q2; $1.381 million for the first half | $2.109 million for Q2 2022; $4.534 million for first-half 2022 |
| General and administrative expense | $2.220 million for Q2; $5.178 million for the first half | $2.137 million for Q2 2022; $4.266 million for first-half 2022 |
| Net loss | $2.113 million for Q2; $6.205 million for the first half | $4.191 million for Q2 2022; $8.717 million for first-half 2022 |
| Cash and cash equivalents | $15.000 million | $10.114 million at December 31, 2022 |
| Marketable securities | None | $12.409 million at December 31, 2022; all had matured by June 30, 2023 |
| Total assets / liabilities | $15.695 million / $1.465 million | $22.635 million / $2.417 million at December 31, 2022 |
| Working capital / accumulated deficit | $14.2 million / $151.8 million | Not separately provided for comparison |
For the six months ended June 30, operating cash use was $7.614 million, versus $8.737 million in the prior-year period. Investing activities provided $12.5 million, primarily from maturities of marketable securities; financing activities provided no cash. The filing reports no debt. Profit margins are not meaningful because the company had no product revenue and incurred losses.
Material changes versus prior periods
- Q2 net loss narrowed by about $2.077 million year over year, mainly as R&D spending fell by about $2.036 million following the wind-down or completion of TSC-related studies and activities. Q2 G&A rose by $83,000, primarily due to merger-related professional fees and severance.
- First-half net loss narrowed by about $2.512 million. Lower R&D expense was partly offset by higher G&A, including merger fees and severance. Interest income increased in both comparative periods, which management attributed mainly to higher interest rates.
- Cash increased from year-end as marketable securities matured; this was a shift in the composition of liquid assets, not operating cash generation.
- A first-quarter reduction in force affected seven of 13 employees and was described as a cash-preservation measure. First-half stock-based compensation was $182,000, down from $556,000.
Outlook, transaction, and risks
Management said June 30 cash and cash equivalents were expected to fund current operations for at least 12 months from the report date, without giving effect to the proposed merger. The company expects continued losses and cash use. It has no committed additional financing; if financing is unavailable, it may further reduce or stop development, change strategy, or cease operations.
The EIP merger required stockholder approval and other closing conditions, including Nasdaq listing approval and at least $12.0 million of “Parent Net Cash” at closing. A stockholder meeting was scheduled for August 15, 2023. The filing estimated post-merger ownership at approximately 24.68% for pre-merger Diffusion stockholders and 75.32% for former EIP equity holders, subject to assumptions and adjustments. A proposed reverse split range of 1-for-1.5 to 1-for-8 was also submitted for approval. If the merger did not close, the company said its most likely alternatives were another strategic transaction or dissolution and liquidation; it might also consider resuming TSC development if funding were available.
EIP’s lead candidate, neflamapimod, was in a 160-subject Phase 2b trial for dementia with Lewy bodies. The filing anticipated an initial readout in the second half of 2024 and said the trial costs were expected to be funded by a $21.0 million NIH grant awarded to EIP.
Contingencies include a long-running lawsuit brought by a former executive, for which the company could not estimate a possible loss or range, and multiple stockholder lawsuits and demand letters challenging merger disclosures. The company said it believed the claims lacked merit but could not assure outcomes or quantify potential costs. A merger termination fee of up to $765,000 could apply in certain circumstances.
Key facts for investors to verify
- Confirm the filing issuer: this 10-Q is for Diffusion Pharmaceuticals Inc., notwithstanding the request metadata’s Cervomed Inc. label.
- Track merger approval, closing conditions, actual Parent Net Cash at closing, final ownership dilution, and the reverse-split outcome.
- Verify available liquidity and cash runway after merger expenses and ongoing operating costs; the 12-month runway statement excludes the merger.
- Assess the consequences if the merger fails, including the stated possibilities of another transaction, liquidation, or a funding-dependent return to TSC development.
- Monitor the former-executive litigation and merger-related stockholder actions, whose potential financial impact was not quantified.